NYSE:BSXMedical Equipment
Boston Scientific (BSX) Is Up 9.7% After Positive SEISMIQ 4CE FRACTURE Trial Data - Has The Bull Case Changed?
Earlier this week, Boston Scientific reported that its pivotal FRACTURE IDE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter met all primary safety and effectiveness endpoints in 420 patients with severely calcified coronary artery disease.
The data showed high rates of freedom from major adverse cardiac events and consistent stent expansion in a particularly hard-to-treat patient group, supporting a regulatory submission for SEISMIQ 4CE.
We’ll now examine how this...